You are here

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
The use of benzodiazepines could be a protective factor for community-acquired pneumonia (CAP) in ≤60-year-old subjects
  1. Jordi Almirall1,
  2. Mateu Serra-Prat2,
  3. Francisco Baron3,
  4. Elisabet Palomera2,
  5. Ignasi Bolíbar4
  1. 1 Intensive Care Unit, Hospital de Mataró, Mataró, Barcelona, Spain, CIBERES Spain
  2. 2 Research Unit, Consorci Sanitari del Maresme, Mataró, Barcelona, Spain
  3. 3 Psychiatric Department, Hospital de Mataró, Mataró, Barcelona, Spain
  4. 4 Department of Clinical Epidemiology and Public Health, Hospital de la Santa Creu i de Sant Pau, Barcelona, Spain
  1. Correspondence to Dr Jordi Almirall, Intensive Care Unit, Hospital de Mataró, Carretera de Cirera s/n, Mataró, Barcelona 08304, Spain; jalmirall{at}csdm.cat

https://doi.org/10.1136/thoraxjnl-2013-203634

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We have read with interest the study of Obiora et al 1 regarding the effect of benzodiazepines (BZs) on the risk of community-acquired pneumonia (CAP). It is concluded that the use of BZs was associated with an increased risk for CAP and CAP-related mortality. However, the effect of BZs in patients with CAP is still a matter of debate. We would like to contribute to this unsolved question, with new data from a previously published population-based case-control study carried out in a sample of 2662 subjects (1336 CAP patients and 1326 controls).2 In fact, not only the …

    View Full Text

    Footnotes

    • Contributors JA, MSP and IB have designed the study, contributed in the field work and write the manuscript. FB has helped in benzodiazepine classification and data interpretation. EP has performed the statistical analysis.

    • Funding This study is supported by FIS ISCIII (grant number FIS P1021151 ISCIII).

    • Competing interests None.

    • Ethics approval Institutional review board of CSdM.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles